Clinical Trials Logo

Generalized Anxiety Disorder clinical trials

View clinical trials related to Generalized Anxiety Disorder.

Filter by:

NCT ID: NCT00738738 Withdrawn - Clinical trials for Generalized Anxiety Disorder

6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)

Start date: January 2009
Phase: Phase 3
Study type: Interventional

This is an open-label, multi-site, 6-month study of an investigational compound in elderly outpatients, age 65 years old or above, to assess the long-term safety and tolerability of the compound in the treatment of elderly subjects with Generalized Anxiety Disorder (GAD).

NCT ID: NCT00735995 Completed - Clinical trials for Generalized Anxiety Disorder

Effectiveness of Cognitive Behavioral Therapy (CBT) for Child Anxiety Disorders in Community Clinics in Norway

Start date: August 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the effectiveness of a cognitive-behavioral intervention for children aged 7 to 12 years with anxiety disorders who are referred to ordinary community clinics. The treatment will be conducted as individual therapy or group therapy.

NCT ID: NCT00735267 Terminated - Clinical trials for Generalized Anxiety Disorder

A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)

Start date: October 2008
Phase: Phase 3
Study type: Interventional

This study will assess the long-term safety and tolerability of 350 to 600 mg/day of PD 0332334 administered in split dose (twice daily) in subjects with Generalized Anxiety Disorder.

NCT ID: NCT00734071 Completed - Clinical trials for Generalized Anxiety Disorder

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.

NCT ID: NCT00731120 Completed - Clinical trials for Generalized Anxiety Disorder

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of 2.5 mg and 10 mg vortioxetine, once daily (QD), in adults with generalized anxiety disorder.

NCT ID: NCT00730691 Completed - Clinical trials for Generalized Anxiety Disorder

Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

Start date: June 2008
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in adults with generalized anxiety disorder.

NCT ID: NCT00711737 Completed - Clinical trials for Generalized Anxiety Disorder

Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months

Start date: September 2008
Phase: N/A
Study type: Observational

The purpose of this study is to explore the changes in metabolic parameters in patients treated with escitalopram for six months for major depression, generalized anxiety disorder or panic disorder, with or without agoraphobia.

NCT ID: NCT00703833 Completed - Clinical trials for Generalized Anxiety Disorder

A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Start date: September 2002
Phase: Phase 2
Study type: Interventional

The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.

NCT ID: NCT00701675 Completed - Clinical trials for Generalized Anxiety Disorder

Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly

Sert-GAD
Start date: October 2005
Phase: Phase 4
Study type: Interventional

Generalized anxiety disorder (GAD) is a very common disorder in the geriatric population with prevalence rates reaching 7% and even higher rates of 8% among elderly veterans. However, despite such high prevalence treating clinicians are presently forced to address treatment issues in this population without the guidance of scientific data. This proposal aims to begin to address this void. In light of emerging information regarding efficacy of the newer anti anxiety agents, specifically the selective serotonin reuptake inhibitors (SSRIs), in the treatment of young adult GAD patients it is time to prospectively evaluate the safety and efficacy of these medications in the treatment of elderly GAD patients. Therefore, this study will examine the effects and safety of the SSRI sertraline at different doses (50mg and 100mg per day) for older patients with GAD.

NCT ID: NCT00688818 Completed - Clinical trials for Major Depressive Disorder

Quetiapine in Co-Morbid Depressive and Anxiety Disorders

Start date: June 2008
Phase: N/A
Study type: Interventional

This multi-centred study will be conducted at three centres. The design will be a randomized, placebo-controlled, parallel-group one. This investigation will evaluate the efficacy of add-on Quetiapine XR (extended release) treatment for patients who meet diagnostic criteria for depressive disorders and one or more comorbid anxiety disorder.